$NBIX: Neurocrine Q3 Revenue Jumps 41% to $1.1B, INGREZZA FY Guidance Raised

$NBIX

$NBIX – Neurocrine Q3 Revenue Jumps 41% to $1.1B, INGREZZA FY Guidance Raised to $2.90B-$2.925B

NEUROCRINE BIOSCIENCES INC

2026-11-02 00:00:00 UTC · SEC_8K · All $NBIX

?? Positive AI Sentiment (+6.8 / 10)

Q3 revenue increased 41% YoY to $1.119B, Non-GAAP net income rose to $346.7M ($3.29/share vs $2.17 YoY).
Raised FY2026 INGREZZA net sales guidance to $2.90B–$2.925B (prior $2.825B–$2.875B).
Lowered FY GAAP SG&A expense outlook to $1.54B–$1.56B while keeping R&D unchanged.